Cargando…

Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors

Breast cancer (BC) is the most common cancer in women. Although standard treatments are successful in patients with BC diagnosed at an early stage, an alternative treatment is required for patients with advanced-stage disease who do not respond to these treatments. The concept of using chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawasdee, Nunghathai, Wattanapanitch, Methichit, Thongsin, Nontaphat, Phanthaphol, Nattaporn, Chiawpanit, Chutipa, Thuwajit, Chanitra, Yenchitsomanus, Pa-Thai, Panya, Aussara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815410/
https://www.ncbi.nlm.nih.gov/pubmed/35119077
http://dx.doi.org/10.3892/ijmm.2022.5095
_version_ 1784645276059828224
author Sawasdee, Nunghathai
Wattanapanitch, Methichit
Thongsin, Nontaphat
Phanthaphol, Nattaporn
Chiawpanit, Chutipa
Thuwajit, Chanitra
Yenchitsomanus, Pa-Thai
Panya, Aussara
author_facet Sawasdee, Nunghathai
Wattanapanitch, Methichit
Thongsin, Nontaphat
Phanthaphol, Nattaporn
Chiawpanit, Chutipa
Thuwajit, Chanitra
Yenchitsomanus, Pa-Thai
Panya, Aussara
author_sort Sawasdee, Nunghathai
collection PubMed
description Breast cancer (BC) is the most common cancer in women. Although standard treatments are successful in patients with BC diagnosed at an early stage, an alternative treatment is required for patients with advanced-stage disease who do not respond to these treatments. The concept of using chemotherapy to sensitize cancer cells to become susceptible to immunotherapy was recently introduced and may be used as an alternative treatment for BC. The chemotherapeutic drug doxorubicin has been reported to sensitize cancer cells; however, the efficacy to sensitize the solid spheroids, in addition to its underlying mechanism regarding how doxorubicin sensitizes BC, has not previously been explored. In the present study, the effectiveness of a combined treatment of doxorubicin and natural killer-92 (NK-92) cells against BC in either 2D or 3D spheroid models, and its association with Fas receptor (FasR) expression, was demonstrated. The BC (MCF7) cell line expressing a higher level of FasR was more sensitive to NK-92 cell killing than the MDA-MB-231 cell line, which expressed a lower level of FasR. A sublethal dose of doxorubicin caused a significant improvement in NK cytotoxicity. Concordantly, a significant reduction in cell viability was observed in the doxorubicin-treated MCF7 spheroids. Notably, flow cytometric analysis revealed significantly increased FasR expression in the MCF7 cells, suggesting the underlying sensitization mechanism of doxorubicin in BC was related to the FasR upregulation. The present findings supported the use of combined doxorubicin and NK immunotherapy in BC treatment.
format Online
Article
Text
id pubmed-8815410
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-88154102022-02-09 Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors Sawasdee, Nunghathai Wattanapanitch, Methichit Thongsin, Nontaphat Phanthaphol, Nattaporn Chiawpanit, Chutipa Thuwajit, Chanitra Yenchitsomanus, Pa-Thai Panya, Aussara Int J Mol Med Articles Breast cancer (BC) is the most common cancer in women. Although standard treatments are successful in patients with BC diagnosed at an early stage, an alternative treatment is required for patients with advanced-stage disease who do not respond to these treatments. The concept of using chemotherapy to sensitize cancer cells to become susceptible to immunotherapy was recently introduced and may be used as an alternative treatment for BC. The chemotherapeutic drug doxorubicin has been reported to sensitize cancer cells; however, the efficacy to sensitize the solid spheroids, in addition to its underlying mechanism regarding how doxorubicin sensitizes BC, has not previously been explored. In the present study, the effectiveness of a combined treatment of doxorubicin and natural killer-92 (NK-92) cells against BC in either 2D or 3D spheroid models, and its association with Fas receptor (FasR) expression, was demonstrated. The BC (MCF7) cell line expressing a higher level of FasR was more sensitive to NK-92 cell killing than the MDA-MB-231 cell line, which expressed a lower level of FasR. A sublethal dose of doxorubicin caused a significant improvement in NK cytotoxicity. Concordantly, a significant reduction in cell viability was observed in the doxorubicin-treated MCF7 spheroids. Notably, flow cytometric analysis revealed significantly increased FasR expression in the MCF7 cells, suggesting the underlying sensitization mechanism of doxorubicin in BC was related to the FasR upregulation. The present findings supported the use of combined doxorubicin and NK immunotherapy in BC treatment. D.A. Spandidos 2022-03 2022-02-01 /pmc/articles/PMC8815410/ /pubmed/35119077 http://dx.doi.org/10.3892/ijmm.2022.5095 Text en Copyright: © Sawasdee et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Sawasdee, Nunghathai
Wattanapanitch, Methichit
Thongsin, Nontaphat
Phanthaphol, Nattaporn
Chiawpanit, Chutipa
Thuwajit, Chanitra
Yenchitsomanus, Pa-Thai
Panya, Aussara
Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors
title Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors
title_full Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors
title_fullStr Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors
title_full_unstemmed Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors
title_short Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors
title_sort doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased fas receptors
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815410/
https://www.ncbi.nlm.nih.gov/pubmed/35119077
http://dx.doi.org/10.3892/ijmm.2022.5095
work_keys_str_mv AT sawasdeenunghathai doxorubicinsensitizesbreastcancercellstonaturalkillercellsinconnectionwithincreasedfasreceptors
AT wattanapanitchmethichit doxorubicinsensitizesbreastcancercellstonaturalkillercellsinconnectionwithincreasedfasreceptors
AT thongsinnontaphat doxorubicinsensitizesbreastcancercellstonaturalkillercellsinconnectionwithincreasedfasreceptors
AT phanthapholnattaporn doxorubicinsensitizesbreastcancercellstonaturalkillercellsinconnectionwithincreasedfasreceptors
AT chiawpanitchutipa doxorubicinsensitizesbreastcancercellstonaturalkillercellsinconnectionwithincreasedfasreceptors
AT thuwajitchanitra doxorubicinsensitizesbreastcancercellstonaturalkillercellsinconnectionwithincreasedfasreceptors
AT yenchitsomanuspathai doxorubicinsensitizesbreastcancercellstonaturalkillercellsinconnectionwithincreasedfasreceptors
AT panyaaussara doxorubicinsensitizesbreastcancercellstonaturalkillercellsinconnectionwithincreasedfasreceptors